| Efficacy of administration of weekly docetaxel combined with platinum as a first-line treatment for patients with advanced non-small cell lung cancer |
|
So Yeon Kim, Hun Mo Ryoo, Sung Hwa Bae, Hyun Young Jung, Kyung Chan Kim, Dae Sung Hyun, Sang Chae Lee, Kyeong Ok Kim, Kyung Hee Lee, Myung Soo Hyun, Young Lan Kweon, Ga Young Kim, Gyu Young Kim, Chi Young Jung, Yeon Jae Kim, Byeung Gi Lee, Jung Lim Lee, Won Sik Lee |
|
고려대학교 의과대학 내과학교실 |
| 원저 : 진행성 비소세포폐암 환자에서 제1차 요법으로서 매주요법 Docetaxel/Platinum 복합항암화학요법의 효과 |
|
김소연, Hun Mo Ryoo, Sung Hwa Bae, Hyun Young Jung, Kyung Chan Kim, Dae Sung Hyun, Sang Chae Lee, Kyeong Ok Kim, Kyung Hee Lee, Myung Soo Hyun, Young Lan Kweon, Ga Young Kim, Gyu Young Kim, Chi Young Jung, Yeon Jae Kim, Byeung Gi Lee, Jung Lim Lee, Won Sik Lee |
|
|
|
|
|
|
| Abstract |
Background : Docetaxel is a highly effective chemotherapeutic agent with proven efficacy for non-small cell lung cancer (NSCLC). However, myelosuppression can be a substantial concern when docetaxel is administered every 3 weeks. Weekly administration of low-dose docetaxel has demonstrated a comparable efficacy together with a distinct toxicity profile with reduced myelosuppression. We conducted a phase Ⅱ study of weekly administration of docetaxel and cisplatin or carboplatin in patients with advanced NSCLC to evaluate efficacy and safety.
Methods
: Twenty-nine patients with advanced or metastatic NSCLC who had not received prior treatment were enrolled in the study. The patients received intravenous infusions of docetaxel (35 mg/m2 on days 1, 8, 15) and cisplatin (75 mg/m2 on day 1) or carboplatin (AUC 6), followed by a week of rest.
Results
: Twenty-six patients were assessable for efficacy and all patients were assessable for toxicity determination. The overall response rate of the regimen was 44.8%. The median survival was 11.3 months, and the 1-year survival rate was 37%. Of the hematologic toxicities, grade 3/4 neutropenia were observed in 12.6% of the patients, but there were no episodes of neutropenic fever. Non-hematologic toxicities were mild.
Conclusions
: With this weekly dosing regimen, although efficacy is comparable, myelosuppression is substantially less, and the overall tolerability profile is better than with dosing every 3 weeks.(Korean J Med 72:625-631, 2007)
Key Words : Weekly dosing, Dcisplatin, Carboplatin, Non-small cell lung Cancer |
| Key Words:
Weekly dosing, Dcisplatin, Carboplatin, Non-small cell lung Cancer |
|
PDF Links
Full text via DOI
Download Citation
